Simvastatin induces apoptosis in human breast cancer cells in a NFκB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa

Thrombosis Research

Volumn 122, Issue 2, 2008, Pages 191-202

  Åberg, Mikael ^a   Wickström, Malin ^a   Siegbahn, Agneta ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Cell signaling; FVIIa; NF B; Statins; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN BCL 2; PROTEIN KINASE B BETA; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; THROMBOPLASTIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL LEVEL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; FACTOR VIIA; FACTOR XA; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, BIOLOGICAL; NF-KAPPA B; SIGNAL TRANSDUCTION; SIMVASTATIN; THROMBOPLASTIN; TRANSCRIPTION, GENETIC;

EID: 44449100667     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.09.017     Document Type: Article

References (60)

1. Pedersen T.R. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
2. Demierre M.F., Higgins P.D., Gruber S.B., Hawk E., and Lippman S.M. Statins and cancer prevention. Nat Rev Cancer 5 (2005) 930-942
3. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., and Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7 (2001) 687-692
4. Chapman-Shimshoni D., Yuklea M., Radnay J., Shapiro H., and Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 31 (2003) 779-783
5. Cafforio P., Dammacco F., Gernone A., and Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26 (2005) 883-891
6. Denoyelle C., Vasse M., Korner M., Mishal Z., Ganne F., Vannier J.P., Soria J., and Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22 (2001) 1139-1148
7. Brown J.H., Del Re D.P., and Sussman M.A. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 98 (2006) 730-742
8. Benitah S.A., Valeron P.F., van A.L., Marshall C.J., and Lacal J.C. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 1705 (2004) 121-132
9. Fritz G., Brachetti C., Bahlmann F., Schmidt M., and Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 87 (2002) 635-644
10. Siegbahn A. Cellular consequences upon factor VIIa binding to tissue factor. Haemostasis 30 Suppl 2 (2000) 41-47
11. Mackman N., Fowler B.J., Edgington T.S., and Morrissey J.H. Functional analysis of the human tissue factor promoter and induction by serum. Proc Natl Acad Sci U S A 87 (1990) 2254-2258
12. Mann K.G. Thrombin formation. Chest 124 (2003) 4S-10S
13. Lip G.Y., Chin B.S., and Blann A.D. Cancer and the prothrombotic state. Lancet Oncol 3 (2002) 27-34
14. Prandoni P., Falanga A., and Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 6 (2005) 401-410
15. Shigemori C., Wada H., Matsumoto K., Shiku H., Nakamura S., and Suzuki H. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 80 (1998) 894-898
16. Ueno T., Toi M., Koike M., Nakamura S., and Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 83 (2000) 164-170
17. Kakkar A.K., Lemoine N.R., Scully M.F., Tebbutt S., and Williamson R.C. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 82 (1995) 1101-1104
18. Hamada K., Kuratsu J., Saitoh Y., Takeshima H., Nishi T., and Ushio Y. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 77 (1996) 1877-1883
19. Sorensen B.B., Rao L.V., Tornehave D., Gammeltoft S., and Petersen L.C. Antiapoptotic effect of coagulation factor VIIa. Blood 102 (2003) 1708-1715
20. Versteeg H.H., Spek C.A., Richel D.J., and Peppelenbosch M.P. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 23 (2004) 410-417
21. Jiang X., Guo Y.L., and Bromberg M.E. Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost 96 (2006) 196-201
22. Lindmark E., and Siegbahn A. Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin. Thromb Res 108 (2002) 77-84
23. Ge L., Shenoy S.K., Lefkowitz R.J., and DeFea K. Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. J Biol Chem 279 (2004) 55419-55424
24. Morris D.R., Ding Y., Ricks T.K., Gullapalli A., Wolfe B.L., and Trejo J. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 66 (2006) 307-314
25. Liu Y., and Mueller B.M. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochem Biophys Res Commun 344 (2006) 1263-1270
26. Hjortoe G.M., Petersen L.C., Albrektsen T., Sorensen B.B., Norby P.L., Mandal S.K., Pendurthi U.R., and Rao L.V. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 103 (2004) 3029-3037
27. Kozma S.C., Bogaard M.E., Buser K., Saurer S.M., Bos J.L., Groner B., and Hynes N.E. The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res 15 (1987) 5963-5971
28. Nakshatri H., Bhat-Nakshatri P., Martin D.A., Goulet Jr. R.J., and Sledge Jr. G.W. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17 (1997) 3629-3639
29. Fritz G., Just I., and Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 81 (1999) 682-687
30. Lovborg H., Nygren P., and Larsson R. Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. Mol Cancer Ther 3 (2004) 521-526
31. Malarstig A., Tenno T., Jossan S., Aberg M., and Siegbahn A. A quantitative real-time PCR method for tissue factor mRNA. Thromb Res 112 (2003) 175-183
32. Perkin-Elmer Corp. ABI PRISM 7700 sequence detection system. User Bulletin #2 (1997) 11-16
33. Floros K.V., Thomadaki H., Katsaros N., Talieri M., and Scorilas A. mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem 385 (2004) 1099-1103
34. Gajate C., Santos-Beneit A.M., Macho A., Lazaro M., Hernandez-De R.A., Modolell M., Munoz E., and Mollinedo F. Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells. Int J Cancer 86 (2000) 208-218
35. Nakatani K., Thompson D.A., Barthel A., Sakaue H., Liu W., Weigel R.J., and Roth R.A. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274 (1999) 21528-21532
36. Zhu Z., Jia J., Lu R., Lu Y., Fu Z., Zhao L., Wang L., Jin M., Zhao L., Gao W., and Yao Z. Expression of PTEN, p27, p21 and AKT mRNA and protein in human BEL-7402 hepatocarcinoma cells in transplanted tumors of nude mice treated with the tripeptide tyroservatide (YSV). Int J Cancer 118 (2006) 1539-1544
37. Hayashi K., Yonemura S., Matsui T., and Tsukita S. Immunofluorescence detection of ezrin/radixin/moesin (ERM) proteins with their carboxyl-terminal threonine phosphorylated in cultured cells and tissues. J Cell Sci 112 Pt 8 (1999) 1149-1158
38. Yonemura S., Hirao-Minakuchi K., and Nishimura Y. Rho localization in cells and tissues. Exp Cell Res 295 (2004) 300-314
39. Meng F., Liu L., Chin P.C., and D'Mello S.R. Akt is a downstream target of NF-kappa B. J Biol Chem 277 (2002) 29674-29680
40. Meng F., and D'Mello S.R. NF-kappaB stimulates Akt phosphorylation and gene expression by distinct signaling mechanisms. Biochim Biophys Acta 1630 (2003) 35-40
41. Catz S.D., and Johnson J.L. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20 (2001) 7342-7351
42. Romashkova J.A., and Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401 (1999) 86-90
43. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., and Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401 (1999) 82-85
44. Mackman N. Regulation of the tissue factor gene. FASEB J 9 (1995) 883-889
45. Ahn K.S., Sethi G., and Aggarwal B.B. Simvastatin potentiates TNF-{alpha}-induced apoptosis through the down-regulation of NF-{kappa}B-dependent antiapoptotic gene products: role of I{kappa}B{alpha} kinase and TGF-beta-activated kinase-1. J Immunol 178 (2007) 2507-2516
46. Anwar K.N., Fazal F., Malik A.B., and Rahman A. RhoA/Rho-associated kinase pathway selectively regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via activation of I kappa B kinase beta and phosphorylation of RelA/p65. J Immunol 173 (2004) 6965-6972
47. Ortego M., Gomez-Hernandez A., Vidal C., Sanchez-Galan E., Blanco-Colio L.M., Martin-Ventura J.L., Tunon J., Diaz C., Hernandez G., and Egido J. HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. J Cardiovasc Pharmacol 45 (2005) 468-475
48. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., and Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 17 (1997) 265-272
49. Hilgendorff A., Muth H., Parviz B., Staubitz A., Haberbosch W., Tillmanns H., and Holschermann H. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther 41 (2003) 397-401
50. Versteeg H.H., Spek C.A., Peppelenbosch M.P., and Richel D.J. Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med 10 (2004) 6-11
51. Abe K., Shoji M., Chen J., Bierhaus A., Danave I., Micko C., Casper K., Dillehay D.L., Nawroth P.P., and Rickles F.R. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A 96 (1999) 8663-8668
52. Shoji M., Hancock W.W., Abe K., Micko C., Casper K.A., Baine R.M., Wilcox J.N., Danave I., Dillehay D.L., Matthews E., Contrino J., Morrissey J.H., Gordon S., Edgington T.S., Kudryk B., Kreutzer D.L., and Rickles F.R. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 152 (1998) 399-411
53. Bromberg M.E., Konigsberg W.H., Madison J.F., Pawashe A., and Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A 92 (1995) 8205-8209
54. Siegbahn A., Johnell M., Rorsman C., Ezban M., Heldin C.H., and Ronnstrand L. Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis. Blood 96 (2000) 3452-3458
55. Blom J.W., Doggen C.J., Osanto S., and Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 (2005) 715-722
56. Taniguchi T., Kakkar A.K., Tuddenham E.G., Williamson R.C., and Lemoine N.R. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 58 (1998) 4461-4467
57. Andreasen P.A., Kjoller L., Christensen L., and Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72 (1997) 1-22
58. Bonetti P.O., Lerman L.O., Napoli C., and Lerman A. Statin effects beyond lipid lowering-are they clinically relevant?. Eur Heart J 24 (2003) 225-248
59. van der Spek E., Bloem A.C., van de Donk N.W., Bogers L.H., van der G.R., Kramer M.H., de W.O., Wittebol S., and Lokhorst H.M. Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 91 (2006) 542-545
60. Koyuturk M., Ersoz M., and Altiok N. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett 250 (2007) 220-228